Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Часто задаваемые вопросы
В каком секторе работает Renovaro Biosciences Inc. (RENB)?
Renovaro Biosciences Inc. относится к сектору Здравоохранение.
Какова текущая цена акций Renovaro Biosciences Inc. (RENB)?
По последним данным, цена акций Renovaro Biosciences Inc. составляет 1,42 $, предыдущее закрытие — 1,42 $.
Выплачивает ли Renovaro Biosciences Inc. (RENB) дивиденды?
Нет, Renovaro Biosciences Inc. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Renovaro Biosciences Inc. (RENB)?
У компании Renovaro Biosciences Inc. бета 0.526, что указывает на более низкую волатильность по сравнению с рынком в целом.
